Rivastigmin

Rivastigmin
Klinički podaci
Prodajno ime	Exelon, Exelon Patch
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	1,5 h
Identifikatori
CAS broj	123441-03-2
ATC kod	N06DA03 (WHO)
PubChem	CID 77991
DrugBank	DB00989
ChemSpider	70377
KEGG	C11766
ChEMBL	CHEMBL636
Hemijski podaci
Formula	C14H22N2O2
Molarna masa	250,337
	SMILES CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C; ;
	InChI InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1 ; Key:XSVMFMHYUFZWBK-NSHDSACASA-N ;

Rivastigmin je organsko jedinjenje, koje sadrži 14 atoma ugljenika i ima molekulsku masu od 250,337 Da.^[1]^[2]^[3]^[4]^[5]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	0
Broj rotacionih veza	5
Particioni koeficijent^[6] (ALogP)	2,6
Rastvorljivost^[7] (logS, log(mol/L))	-2,4
Polarna površina^[8] (PSA, Å²)	32,8

Reference

^ Camps, P.; Muñoz-Torrero, D. (фебруар 2002). „Cholinergic drugs in pharmacotherapy of Alzheimer's disease”. Mini Reviews in Medicinal Chemistry. 2 (1): 11—25. PMID 12369954. doi:10.2174/1389557023406638.
^ Rosler, M.; Anand, R.; Cicin-Sain, A.; Gauthier, S.; Agid, Y.; Dal-Bianco, P.; Stahelin, H. B.; Hartman, R.; Gharabawi, M.; Bayer, T. (март 1999). „Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw”. BMJ. 318 (7184): 633—8. PMC 27767 . PMID 10066203. doi:10.1136/bmj.318.7184.633.
^ Finkel, S. I. (јул 2004). „Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease”. Clinical Therapeutics. 26 (7): 980—90. PMID 15336465. doi:10.1016/s0149-2918(04)90172-5.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Rivastigmine

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Camps, P.; Muñoz-Torrero, D. (фебруар 2002). „Cholinergic drugs in pharmacotherapy of Alzheimer's disease”. Mini Reviews in Medicinal Chemistry. 2 (1): 11—25. PMID 12369954. doi:10.2174/1389557023406638.

[2] Rosler, M.; Anand, R.; Cicin-Sain, A.; Gauthier, S.; Agid, Y.; Dal-Bianco, P.; Stahelin, H. B.; Hartman, R.; Gharabawi, M.; Bayer, T. (март 1999). „Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw”. BMJ. 318 (7184): 633—8. PMC 27767 . PMID 10066203. doi:10.1136/bmj.318.7184.633.

[3] Finkel, S. I. (јул 2004). „Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease”. Clinical Therapeutics. 26 (7): 980—90. PMID 15336465. doi:10.1016/s0149-2918(04)90172-5.

[4] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[5] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[6] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[7] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[8] Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]